A two year experience of DNA diagnosis for NF1 is presented. Twenty-three NFI families have been analysed using 11 closely linked and intragenic markers. Prenatal testing was undertaken for six families; 11 affected subjects and their partners wished to know if they would be informative for future prenatal testing, seven of whom are so far fully informative. Presymptomatic testing was done for six subjects. Despite the availability of a series of closely linked markers, informativeness could not be achieved in all of the families tested. With the availability of closely linked and intragenic markers, it has been possible to provide prenatal and heterozygote testing for NF1. We report here our experience over a two year period of providing a diagnostic service for NF1 using DNA markers.
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition, affecting around 1 in 3000 subjects. The disease is typically characterised by cafe au lait spots, neurofibromas, and Lisch nodules. The main problems in NF1 arise secondary to disease complications, which are extremely variable and the occurrence cannot be predicted even within families. The gene for NFl was mapped to chromosome 17 in 19873 3 and several close flanking markers were defined subsequently.56 Balanced translocations involving chromosome band 17ql 1.2 were reported in two unrelated NF1 patients7 8; the breakpoints on chromosome 17 were 60 kb apart. 9 Positional cloning (reverse genetic) techniques have enabled the gene to be cloned.'01' Using a RNA PCR based assay,'0 it was confirmed that translocations prevented transcription of the NFl gene on the affected chromosome 17 and NFI1 cDNAs were interrupted by both translocation breakpoints."' 12 The NF 1 gene has been reported to be interrupted by four deletions, 11 kb, 40 kb, 160 kb, and 90 kb,"l 3 one insertion, and three point mutations.'4 Such specific changes are so far too infrequent to be of clinical application outside these rare specific families.
With the availability of closely linked and intragenic markers, it has been possible to provide prenatal and heterozygote testing for NF1. We report here our experience over a two year period of providing a diagnostic service for NF1 using DNA markers.
Material and methods
The families used in the analysis were referred from clinical genetics centres in Britain and elsewhere in Europe. Blood for DNA samples, clinical data, and pedigree data were provided by the referring centre after full discussion with us. Chorionic villus tissue or DNA were sent by courier.
Whole blood for DNA extraction was collected in EDTA tubes. The DNA was digested with appropriate restriction enzymes (MspI, RsaI, EcoRI, PstI, BamHI, HindIII, BglII, TaqI) and fractionated on 0 7 to 0 8% agarose gel before transfer by Southern blotting to Hybond N (Amersham) filters. DNA probes were labelled with 32P using the primer extension method'5 and hybridised to filters at 65'C.
The posthybridisation wash was in 2 x SSC, 0 1% SDS; the stringency of washing was increased as necessary. The hybridised membrane was exposed to x ray film at -70°for between one and seven days.
Clinical requests were of three types: prenatal diagnosis in a continuing pregnancy, suitability for future prenatal diagnosis, and assignment of genotype in clinically normal subjects at risk.
Two point linkage analysis for risk estimation was done using the program MLINK. Allele frequencies were determined for the founder of each NFl family and the spouses. to the pregnancy was reduced from 50% to 4%. A healthy son has since been born. The proband (NF 502 3) wished to know whether she would be informative for future prenatal testing. The family was analysed initially using closely linked markers and also with distant markers so that haplotypes could be constructed. The couple were partially informative for future prenatal diagnosis using probe 38.2. The couple were counselled on the significance of these DNA results and in a subsequent pregnancy they opted to have prenatal diagnosis; the risk to the fetus was reduced from 50% to 4%. CASE 3 This family (NF 506) was referred to us from Finland at 10 weeks' gestation (Dr M Ryynanen). The couple was informative using flanking DNA markers HHH202, proximal to the disease locus, and C11. This pregnancy was referred at 8 weeks' gestation from Israel (Dr J Zlotogora); the proband (NF 511-2) was considered to be a new mutation. Her clinical features included cafe au lait spots and neurofibromas. She had an affected son who had cafe au lait spots only. The couple requested prenatal diagnosis and were informative using intragenic marker pRC9.4. Chorion biopsy was taken at 12 weeks and DNA was sent in ethanol. The genotype of the fetus was the same as that of the affected sib giving a risk approaching 100%. The pregnancy was terminated before the DNA result was available because the karyotype showed a 45,X (Turner) fetus. CASE 6 In this family, the proband (NF 513 4) had an affected father and unaffected daughter. Because of the lack of availability of prenatal diagnosis, her husband had had a vasectomy in the past. If informative for prenatal diagnosis the husband was going to have a reversal of sterilisation. This family has been analysed using 10 DNA markers, but an informative situation could not be reached. CASE 7 This family (NF 519, table 4) was referred for DNA analysis during the first trimester of pregnancy. The DNA analysis was done rapidly and showed that the couple were suitable for prenatal diagnosis using an intragenic probe. They decided against prenatal diagnosis but a subsequent amniocentesis was carried out because of advanced maternal age and DNA from amniocytes was banked. Presymptomatic testing of the banked fetal DNA was done in the third trimester at the family's request because of excessive anxiety of the mother. The fetus carried the low risk allele. A healthy son has since been born. CASE 8 In this family, the mother (NF 514 3, family situation is different and each request should be discussed fully with the family. The results of DNA studies should always be combined with clinical examination in order to reduce errors in the assignment of genetic status.
One study involving presymptomatic detection and informativeness for prenatal testing in NF1 has already been reported. 20 The results reported in our paper are the first to include prenatal diagnosis. We have found the demand for prenatal diagnosis to be limited. In addition to the six pregnancies described here, two families were referred for analysis during pregnancy, were informative for DNA markers, but decided against prenatal testing. The main reason for not choosing to have prenatal testing in the majority of cases was that the parents would only want to consider a test which would predict disease severity. Our series also shows that it cannot be guaranteed that all couples will be informative for prenatal diagnosis, even with available closely linked markers. In addition it is preferable to perform DNA informativeness analysis before a pregnancy is undertaken. The observed outcome of the completed pregnancies have not shown any error, but since the disease is not fully penetrant until the age of 5 the final outcome is still awaited. However, in family NF 506, where DNA analysis predicted a high risk pregnancy, a female child with multiple cafe au lait spots was born.
Direct analysis of specific mutations or deletions is currently possible for only a very small proportion of families with NFL, but this is likely to change rapidly as the detailed structure of this large gene becomes better understood. The detection of specific mutations will permit specific prenatal diagnosis independent of family structure and will be of particular help for the large numbers of isolated cases. Mutation analysis will also establish whether cases of NFI with unusual phenotype are indeed determined by the same locus and will thus allow genetic testing to be undertaken for these families.
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